A Phase III Study Assessing the Addition of Atezolizumab Immunotherapy to the Usual Radiation Treatment for Patients with Early Non-Small Cell Lung Cancer

Share
Print

Full Title

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC (S1914) (CIRB)

Purpose

Radiation therapy, such as stereotactic body radiation therapy (SBRT), uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. In this study, researchers want to see if adding the immunotherapy drug atezolizumab to SBRT is more effective than SBRT alone for patients with inoperable early-stage non-small cell lung cancer (NSCLC).

Atezolizumab boosts the power of the immune system to identify and destroy cancer cells. Patients in this study will be randomly assigned to receive atezolizumab plus SBRT or SBRT alone. Atezolizumab is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable early-stage NSCLC that has not spread to the lymph nodes and has not yet been treated.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dominique McKnight at 646-888-1326.

Protocol

20-295

Phase

III

Investigator

Co-Investigators